JP2020536916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536916A5 JP2020536916A5 JP2020520535A JP2020520535A JP2020536916A5 JP 2020536916 A5 JP2020536916 A5 JP 2020536916A5 JP 2020520535 A JP2020520535 A JP 2020520535A JP 2020520535 A JP2020520535 A JP 2020520535A JP 2020536916 A5 JP2020536916 A5 JP 2020536916A5
- Authority
- JP
- Japan
- Prior art keywords
- drug conjugate
- antibody
- administered
- antibody drug
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 94
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 94
- 230000004936 stimulating effect Effects 0.000 claims description 39
- 201000005962 mycosis fungoides Diseases 0.000 claims description 28
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 27
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 27
- 208000017604 Hodgkin disease Diseases 0.000 claims description 22
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 18
- 201000005787 hematologic cancer Diseases 0.000 claims description 17
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 17
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 16
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 16
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 16
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 16
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 15
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 15
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 13
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 10
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims description 10
- 229960003901 dacarbazine Drugs 0.000 claims description 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 10
- 229960003048 vinblastine Drugs 0.000 claims description 10
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 9
- 229960004679 doxorubicin Drugs 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000002648 combination therapy Methods 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 208000004235 neutropenia Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 210000003714 granulocyte Anatomy 0.000 claims 6
- 239000000562 conjugate Substances 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 101800001707 Spacer peptide Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 103
- 108010006654 Bleomycin Proteins 0.000 description 4
- 229960001561 bleomycin Drugs 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000007775 late Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 206010021925 Inferiority complex Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010034580 Peripheral motor neuropathy Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000002239 motor neuritis Diseases 0.000 description 1
- 201000005545 motor peripheral neuropathy Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- INIBXSLTWQVIHS-ASACRTLUSA-O stanford v protocol Chemical compound ClCCN(C)CCCl.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C INIBXSLTWQVIHS-ASACRTLUSA-O 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116434A JP7750902B2 (ja) | 2017-10-11 | 2023-07-18 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
| JP2025158913A JP2026001086A (ja) | 2017-10-11 | 2025-09-25 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570901P | 2017-10-11 | 2017-10-11 | |
| US62/570,901 | 2017-10-11 | ||
| US201762580267P | 2017-11-01 | 2017-11-01 | |
| US62/580,267 | 2017-11-01 | ||
| US201862639308P | 2018-03-06 | 2018-03-06 | |
| US62/639,308 | 2018-03-06 | ||
| US201862764805P | 2018-08-16 | 2018-08-16 | |
| US62/764,805 | 2018-08-16 | ||
| PCT/US2018/055354 WO2019075168A2 (en) | 2017-10-11 | 2018-10-11 | METHODS OF REDUCING SIDE EFFECTS OF DRUG-CONJUGATED DRUG THERAPY ANTI-CD30 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116434A Division JP7750902B2 (ja) | 2017-10-11 | 2023-07-18 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536916A JP2020536916A (ja) | 2020-12-17 |
| JP2020536916A5 true JP2020536916A5 (enExample) | 2021-11-25 |
Family
ID=64477266
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520535A Withdrawn JP2020536916A (ja) | 2017-10-11 | 2018-10-11 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
| JP2023116434A Active JP7750902B2 (ja) | 2017-10-11 | 2023-07-18 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
| JP2025158913A Pending JP2026001086A (ja) | 2017-10-11 | 2025-09-25 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116434A Active JP7750902B2 (ja) | 2017-10-11 | 2023-07-18 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
| JP2025158913A Pending JP2026001086A (ja) | 2017-10-11 | 2025-09-25 | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11795229B2 (enExample) |
| EP (1) | EP3694559A2 (enExample) |
| JP (3) | JP2020536916A (enExample) |
| KR (2) | KR20200066676A (enExample) |
| CN (1) | CN111526893A (enExample) |
| AU (1) | AU2018347406B2 (enExample) |
| BR (1) | BR112020006892A2 (enExample) |
| CA (1) | CA3078737A1 (enExample) |
| IL (2) | IL316538A (enExample) |
| MA (1) | MA50767A (enExample) |
| MX (1) | MX2020003664A (enExample) |
| SG (1) | SG11202003352SA (enExample) |
| TW (1) | TW201922281A (enExample) |
| WO (1) | WO2019075168A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102770340B1 (ko) | 2020-06-02 | 2025-02-21 | 삼성디스플레이 주식회사 | 표시 패널 및 이를 구비하는 표시 장치 |
| KR20230047114A (ko) * | 2020-08-03 | 2023-04-06 | 제넨테크, 인크. | 공격성 비호지킨 림프종에서의 내약성 예측 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1828241A1 (en) * | 2004-12-23 | 2007-09-05 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
| CA2699090C (en) * | 2007-10-12 | 2016-02-02 | Seattle Genetics, Inc. | Combination therapy with antibody-drug conjugates |
| CA3051090C (en) | 2009-01-09 | 2022-04-12 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
-
2018
- 2018-10-11 WO PCT/US2018/055354 patent/WO2019075168A2/en not_active Ceased
- 2018-10-11 TW TW107135857A patent/TW201922281A/zh unknown
- 2018-10-11 CA CA3078737A patent/CA3078737A1/en active Pending
- 2018-10-11 KR KR1020207012961A patent/KR20200066676A/ko active Pending
- 2018-10-11 JP JP2020520535A patent/JP2020536916A/ja not_active Withdrawn
- 2018-10-11 CN CN201880075981.2A patent/CN111526893A/zh active Pending
- 2018-10-11 AU AU2018347406A patent/AU2018347406B2/en active Active
- 2018-10-11 BR BR112020006892-6A patent/BR112020006892A2/pt unknown
- 2018-10-11 SG SG11202003352SA patent/SG11202003352SA/en unknown
- 2018-10-11 MA MA050767A patent/MA50767A/fr unknown
- 2018-10-11 EP EP18808554.2A patent/EP3694559A2/en active Pending
- 2018-10-11 US US16/755,403 patent/US11795229B2/en active Active
- 2018-10-11 MX MX2020003664A patent/MX2020003664A/es unknown
- 2018-10-11 IL IL316538A patent/IL316538A/en unknown
- 2018-10-11 KR KR1020257025342A patent/KR20250117487A/ko active Pending
-
2020
- 2020-04-07 IL IL273874A patent/IL273874A/en unknown
-
2023
- 2023-07-18 JP JP2023116434A patent/JP7750902B2/ja active Active
-
2025
- 2025-09-25 JP JP2025158913A patent/JP2026001086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9790278B2 (en) | Anti-B7-H6 antibody, fusion proteins, and methods of using the same | |
| ES2563439T5 (es) | Medios y métodos para tratar LDCBG | |
| AU2018225177A1 (en) | Therapeutic compositions and related methods for photoimmunotherapy | |
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP2004533449A (ja) | Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体 | |
| JP2020520382A5 (enExample) | ||
| JP2009530361A (ja) | 免疫細胞刺激のための可逆的に阻害された抗体 | |
| JPH05504677A (ja) | ＩｇＡレセプターに特異的なモノクロナール抗体 | |
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| JP2020536916A5 (enExample) | ||
| KR20210102917A (ko) | 종양 질환을 치료하기 위한 il-15 단백질 복합체 연합 pd-l1 항체의 용도 | |
| Choy et al. | Chimaeric anti‐CD4 monoclonal antibody cross‐linked by monocyte Fcγ receptor mediates apoptosis of human CD4 lymphocytes | |
| JP2021501800A5 (enExample) | ||
| BR112020008375A2 (pt) | métodos de reduzir efeitos colaterais de terapia conjugada com fármacos de anticorpo anti-cd30 | |
| Nepom et al. | Challenges in the pursuit of immune tolerance | |
| Kok et al. | Sarcoid‐like lymphadenopathy mimicking metastatic testicular cancer | |
| Bogucka-Fedorczuk et al. | Bispecific antibodies in the treatment of follicular lymphoma | |
| US11814436B2 (en) | Anti-CD30 monoclonal antibodies and chimeric antigen receptors | |
| JP7659546B2 (ja) | 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用 | |
| JP2002521491A (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| Mauch et al. | International Database on Hodgkin's Disease: A cooperative effort to determine treatment outcome | |
| Barrera-Rodríguez et al. | Immuno-and Targeted Therapies for Cancer | |
| Arredondo-Garzaa et al. | Peri-Infusional Adverse Reactions to Rituximab in Mexican Patients with Rheumatoid Arthritis | |
| Radman et al. | Monoklonska protutijela u liječenju ne-Hodgkinovih limfoma | |
| Panayi | Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fcy receptor mediates apoptosis of human CD4 lymphocytes |